SCHEMBL1011983

SCHEMBL1011983

COC(=O)C1C(=O)C(C(=O)OC)C2CCC1N2Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.54
SLC6A3 Q01959 2/20 0.54
CYP1A2 P05177 1/20 0.54
HIF1A Q16665 1/20 0.54
CYP3A4 P08684 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
FKBP1A P62942 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011753 0.86 ALDH1A1 (0.50) SLC6A4KMT2AALDH1A1NPSR1
SCHEMBL1015012 0.85 SLC6A4 (0.54) SLC6A4SLC6A3CYP3A4KMT2AALDH1A1
SCHEMBL1011495 0.85 SLC6A4 (0.54) SLC6A4SLC6A3CYP3A4KMT2AALDH1A1
SCHEMBL1010278 0.85 SLC6A4 (0.43) SLC6A4SLC6A3CYP1A2HIF1ACYP3A4
SCHEMBL1010837 0.84 FKBP1A (0.47) SLC6A3ALDH1A1FKBP1ASMN1; SMN2HPGD
SCHEMBL7652967 0.83 CYP2C19 (0.46) SLC6A4SLC6A3CYP3A4KMT2AALDH1A1
SCHEMBL1010262 0.82 L3MBTL1 (0.43) SLC6A4SLC6A3CYP3A4ALDH1A1KDM4E
SCHEMBL11099778 0.81 SLC6A4 (0.60) SLC6A4SLC6A3CYP3A4KMT2AALDH1A1
SCHEMBL15406170 0.79 FKBP1A (0.56) SLC6A4SLC6A3CYP3A4KMT2AALDH1A1
SCHEMBL5965409 0.79 FKBP1A (0.56) SLC6A4SLC6A3CYP3A4KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1118674-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE NIHON MEDIPHYSICS CO LTD (JP) 2011-01-05 EP disclosed
US-20030065183-A1 Process for producing optically active tropinonemonocarboxylic acid ester derivative NIHON MEDI-PHYSICS CO., LTD. 2003-04-03 US disclosed
US-6486323-B1 Process for producing optically active tropinonemonocarboxylic acid derivative NIHON MEDI-PHYSICS CO., LTD. (JP) 2002-11-26 US disclosed
EP-1118674-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE Nihon Medi-Physics Co., Ltd. (JP) 2001-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065183-A1 Process for producing optically active tropinonemonocarboxylic acid ester derivative CES2, FTO, HAAO SLC6A4 1204/4885SLC6A3 712/4885CYP1A2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.